From Smartphones to AI: ARM's Expanding Global Tech Influence
What sets ARM apart is its unmatched ability to deliver high performance with minimal power consumption, an increasingly critical requirement as the world becomes more connected and intelligent. From wearables to cloud data centers, AI workloads are proliferating across device categories, and Arm Holdings' flexible, energy-efficient architecture is being adopted to meet these next-generation demands.
Apple continues to rely heavily on Arm Holdings' architecture, using it as the backbone for its M-series chips and accelerating AI integration across its ecosystem. Qualcomm, a long-time partner, leverages Arm Holdings' designs in its Snapdragon processors to fuel AI-driven innovations in smartphones and automotive platforms. Samsung, too, embeds Arm technology in its mobile and consumer electronics devices while advancing AI and IoT capabilities through its Exynos chipsets.
The reliance on ARM by these tech leaders isn't just continuing — it's deepening. As Apple, Qualcomm and Samsung scale up their AI ambitions and broaden their IoT strategies, Arm Holdings remains central to enabling this transformation through its scalable power efficiency. The company's commitment to optimizing its architecture for machine learning and edge computing further strengthens its alignment with the strategic needs of its top clients.
In this light, Arm Holdings is no longer just a key player in mobile chip design — it is fast becoming an essential infrastructure layer powering the AI and IoT future for Apple, Qualcomm and Samsung. Its growing role cements its position as a critical enabler in the broader technology ecosystem.
ARM's Price Performance, Valuation & Estimates
The stock has climbed 41% in the past three months, underperforming the industry 's 45% growth.
From a valuation standpoint, ARM trades at a forward price-to-sales ratio of 30.92, well above the industry's 8.64. It carries a Value Score of F.
The Zacks Consensus Estimate for ARM's earnings has remained unchanged over the past 30 days.
ARM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QUALCOMM Incorporated (QCOM): Free Stock Analysis Report
Apple Inc. (AAPL): Free Stock Analysis Report
ARM Holdings PLC Sponsored ADR (ARM): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
32 minutes ago
- Globe and Mail
Global Artificial Intelligence in Oncology Market Size to Hit USD 2,145.1 Million by 2025, grow at a CAGR of 33.7%
Artificial intelligence (AI) is playing an increasingly important role in oncology. There are various types of AI products that are helping in cancer screening, diagnosis, treatment, and drug development. One of the major products is an AI-assisted cancer screening tool. These tools use deep learning algorithms that have been trained on huge databases of medical images. Global Artificial Intelligence in Oncology Market Key Takeaways According to Coherent Market Insights (CMI), the global artificial intelligence in oncology market size is expected to grow more than 7.6X, from USD 2,145.1 Mn in 2025 to USD 16,382 Mn by 2032, exhibiting a robust CAGR of 33.7%. Based on component, software/platform segment is anticipated to account for a prominent market share of 64.2% in 2025. North America is expected to retain its dominance, accounting for more than one-third of the global artificial intelligence in oncology market share in 2025. Europe is projected to remain the second-leading market for AI-powered oncology companies. As per Coherent Market Insights' new global artificial intelligence in oncology market analysis, Asia Pacific is poised to witness fastest growth throughout the assessment period. Increasing Cancer Prevalence Spurring Market Growth Coherent Market Insights' latest global artificial intelligence in oncology market research report highlights key factors driving market growth. One such prominent growth factor is the rising incidence of cancer. The IARC's Global Cancer Observatory projects that annual new cancer cases will surpass 35 million by 2050. This sharp rise in cancer incidence is anticipated to drive demand for artificial intelligence in oncology. Artificial intelligence is revolutionizing oncology by enhancing cancer detection, treatment planning, and drug discovery. Therefore, growing cancer burden is poised to play a crucial role in driving adoption of AI-based oncology solutions over the forecast period. High Implementation Costs and Data Privacy Concerns Restraining Market Growth The global artificial intelligence in oncology market outlook indicates strong future growth. However, high implementation costs and data security concerns are limiting market growth to some extent. Integrating AI technologies into oncology workflows requires significant investment in hardware and software. This deters small and mid-sized healthcare companies from opting for these technologies, thereby reducing global artificial intelligence in oncology market demand. AI systems require access to large amounts of patient data, raising concerns about cybersecurity risks as well as potential misuse. This may also negatively impact the global artificial intelligence in oncology market growth during the projection period. Get Instant Access! Purchase Research Report and Receive a 25% Discount: Technological Advancements in AI Creating New Growth Prospects for the Market Ongoing innovations in deep learning, computer vision, and natural language processing (NLP) are significantly enhancing AI applications in image analysis, drug discovery, and prognosis prediction. Such breakthroughs are expected to unlock new revenue-generation streams for industry players. Advanced AI technologies are being increasingly integrated with imaging modalities like MRI and PET scans. This integration enables automated detection of anomalies, enhances diagnostic accuracy, and reduces human error. Emerging Global Artificial Intelligence in Oncology Market Trends Rising demand for precision medicine is a key growth-shaping trend in the market. Precision oncology requires analyzing large datasets, including genomics and biomarkers. This is where AI steps in, processing huge data and enabling creation of individualized therapies. Expanding use of artificial intelligence in radiology and pathology is expected to boost the market. AI technologies are being increasingly used for tumor detection, segmentation, and classification through radiological and histopathological images. This is due to their ability to improve speed and consistency as well as reduce diagnostic errors. Increasing adoption of AI in drug discovery and development is positively impacting the global artificial intelligence in oncology market value. This advanced technology is revolutionizing drug discovery by rapidly analyzing large datasets to identify potential drug candidates as well as predict their efficacy and toxicity. Growing adoption of cloud-based AI solutions is significantly contributing to the expansion of the global artificial intelligence in oncology market. These solutions are increasingly favored for their cost-efficiency, scalability, and ability to provide seamless remote access to data and tools. Analyst's View ' The global artificial intelligence in oncology market is set for rapid expansion, owing to growing prevalence of cancer, rising adoption of precision medicine, and technological advancements in AI technologies,' said senior analyst Komal Dighe. Current Events and Their Impact on the Global Artificial Intelligence in Oncology Market Event Description and Impact FDA Clears First GenAI-Powered Diagnostic Tool for Breast Cancer Detection (2025) Description: The U.S. FDA approved a GenAI-based diagnostic platform by PathIntel, capable of identifying breast cancer subtypes with high accuracy using real-world data. Impact: Such approvals signal growing regulatory acceptance of generative AI in oncology. Tempus Collaborated with Boehringer to Accelerate AI Usage in Oncology Description: In May 2025, Tempus entered a multi-year strategic collaboration with Boehringer Ingelheim to apply its AI-driven oncology insights toward cancer‑focused therapeutic discovery and biomarker development Impact: This will likely boost growth of the AI in oncology market. Japan's MHLW Updates Reimbursement Guidelines for AI Diagnostics Description: Japanese Ministry of Health, Labour and Welfare (MHLW) has approved reimbursement for certain AI-enhanced imaging diagnostics Impact: Such initiatives will increase commercial viability and adoption of AI oncology tools in Asia-Pacific, spurring more localized R&D and product launches. Competitor Insights Key companies listed in the global artificial intelligence in oncology market report: - IBM Corporation - Intel Corporation - Azra AI - NVIDIA Corporation - Siemens Healthineers AG - GE HealthCare - Digital Diagnostics Inc. - ConcertAI - PathAI - Median Technologies - Microsoft - Babylon - Zebra Medical Vision Key Developments In June 2025, launched a new strategic alliance with Novartis to accelerate timely diagnosis and deliver AI-powered precision care for cancer patients. Through this collaboration, will focus on developing AI-powered workflows for breast and prostate cancer. In November 2024, PathAI unveiled PathExplore Fibrosis. This new AI-powered tool is designed to revolutionize collagen, fibrosis, and fiber quantification directly from whole-slide images. In January 2024, PathAI launched six additional oncology indications for PathExplore, expanding the AI-driven pathology panel to cover ovarian, bladder, liver, small cell lung, lymphoma, and head & neck cancers. Global Artificial Intelligence in Oncology Market Segmentation: By Component Software/Platform Hardware Services By Cancer Type Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Brain Tumor Others By Treatment Type Chemotherapy Radiotherapy Immunotherapy Others By End User: Hospitals & Clinics Diagnostic Centers Biopharmaceutical Companies Others By Region North America Latin America Europe Asia Pacific Middle East Africa About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Globe and Mail
32 minutes ago
- Globe and Mail
Metagenomics Market Advancing with Microbiome Research Breakthroughs and Expanding Applications in Healthcare and Agriculture, 2025-2032
According to a recent report by Coherent Market Insights, the global Metagenomics Market is estimated to be valued at USD 2.36 Bn in 2025 and is expected to reach USD 4.13 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032. The growing use of metagenomics across diverse industries such as healthcare and biotechnology is expected to drive market growth. Metagenomics offers a wide range of applications, including gene identification for disease treatment, microbiome analysis, biofuel production, and environmental cleanup. Additionally, advancements in sequencing technologies and declining sequencing costs are projected to support the expansion of the metagenomics sector. Increasing global research efforts in this field are also anticipated to further boost market growth during the forecast period. Request a Sample Copy of this Report at: Global Metagenomics Market Key Takeaways According to Coherent Market Insights (CMI), the global metagenomics market size is estimated to reach USD 2.36 Bn in 2025 and USD 4.13 Bn by 2032, registering a CAGR of 8.3%. Based on product, reagents & consumables segment is expected to dominate the industry, accounting for a revenue of about USD 1.30 Bn in 2025. By technology, shotgun sequencing segment is set to account for more than two-fifths of the global metagenomics market share in 2025. Based on application, drug discovery segment is likely to hold a market share of 52.8% in 2025 As per Coherent Market Insights' latest metagenomics market analysis, North America is expected to retain its dominance, accounting for 38% of the global market share in 2025. Asia Pacific metagenomics market is poised to experience fastest growth during the assessment period. Rising Prevalence of Chronic and Infectious Diseases Fueling Market Growth A new report by Coherent Market Insights outlines prominent metagenomics market growth factors. One such growth driver is the increasing incidence of chronic and infectious diseases worldwide. Rise in chronic and infectious diseases necessitates rapid and accurate identification of pathogens, including rare and complex microbial infections. This is where metagenomics steps in. Metagenomics offers a powerful tool for identifying novel pathogens as well as analyzing disease-related microbiomes. Thus, rising prevalence of chronic and infectious diseases, coupled with growing demand for enhanced diagnostics technologies, is expected to boost growth of metagenomics market during the forecast period. Purchase Now Up to 25% Discount on This Premium Report @ High Cost of Sequencing Technologies Restraining Market Growth The future metagenomics market outlook looks bright. However, high cost of advanced metagenomic sequencing instruments poses a barrier to widespread market expansion. Sequencing platforms required for advanced metagenomic analysis are quite expensive. This limits their adoption, especially across low- and middle-income regions, thereby reducing overall metagenomics market demand. Advancements in Genomic Technologies Opening New Growth Opportunities Ongoing innovations in next-generation sequencing (NGS), shotgun metagenomics, and bioinformatics tools are making metagenomics studies faster as well as more accurate and cost-effective. These technological advancements are expected to unlock new growth opportunities for metagenomics companies during the forecast period. Impact of AI on the Metagenomics Market Artificial Intelligence (AI) is emerging as a powerful tool in the metagenomics market. It has the potential to enhance data analysis, pattern recognition, and predictive modeling. AI tools speed up and improve the analysis of complex microbial data. They help identify new microorganisms, gene functions, and disease links more precisely. This accelerates the discovery of therapeutic targets, environmental monitoring, and microbiome research. Leading players like Thermo Fisher Scientific and Illumina are increasing this AI trend. For instance, in 2025, Thermo Fisher Scientific launched a new AI-enhanced metagenomics data analytics platform aimed at improving accuracy and speed of microbial classification. Emerging Metagenomics Market Trends Growing demand for precision medicine is a key growth-shaping trend in the market. Metagenomics provides insights into the microbiome's role in health and diseases, thereby enabling the development of targeted therapies. Many nations are increasingly investing in microbiome research projects like the Human Microbiome Project. This will further boost metagenomics market growth during the forecast period. Expanding applications in environmental and agricultural microbiology are expected to play a key role in boosting the metagenomics market value. Metagenomics is being widely used to assess microbial diversity in water, soil, and waste treatment systems. There is also a growing trend of using AI and ML for analyzing vast metagenomic datasets. Such innovations are expected to create lucrative opportunities for metagenomic product manufacturers. Analyst's View ' The global metagenomics industry is expected to experience rapid growth, owing to rising incidence of chronic and infectious diseases, expanding usage of metagenomics in drug discovery, and advancements in genomic technologies,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Metagenomics Market Event Description and Impact Post-Pandemic Acceleration of Genome Research Funding Description: Global research funding for microbiome studies is increasing, with emphasis on infectious disease surveillance and pandemic preparedness. Impact: This drives demand for clinical-grade metagenomic platforms for rapid pathogen detection and variant tracking. AI & Deep Learning Revolution in Microbiome Analysis Description: LLMs and AI tools are now being used for microbial functional annotation and strain-level resolution. Impact: These technologies improve the speed and accuracy of interpreting complex metagenomic datasets, enhancing applications across clinical diagnostics, environmental monitoring, and agriculture. Strategic M&A Activity Description: In May 2025, Mapmygenome (India) acquired Canadian CRO Microbiome Insights to scale up global sequencing operations. Impact: Such strategic mergers and acquisitions strengthen international presence and diversify service portfolios, fostering market consolidation in the metagenomics sector. Competitor Insights Key companies listed in metagenomics market report: - Illumina, Inc. - Bio-Rad Laboratories, Inc. - QIAGEN - PerkinElmer, Inc. - Novogene Co., Ltd. - Thermo Fisher Scientific, Inc. - Promega Corporation - Oxford Nanopore Technologies - Takara Bio, Inc. - PacBio - F. Hoffmann-La Roche Ltd Key Developments In April 2025, Metabolon introduced the Microbiome Research Solution for high-quality metagenomics and metabolomics data. It combines novel microbiome panel, metagenomics sequencing, and multiomics bioinformatics tools to create the industry's most powerful microbiome research toolkit. In July 2024, MGI Tech launched Human Microbiome Metagenomics Sequencing Package. This comprehensive solution encompasses the full workflow of human microbiome metagenomics sequencing, from sample collection and extraction to library preparation, sequencing, and analysis. The package features high automation and flexible throughput. Market Segmentation Product Insights (Revenue, USD Bn, 2020 - 2032) Reagents & Consumables Instruments Sequencing & Data Analytics Services Technology Insights (Revenue, USD Bn, 2020 - 2032) Shotgun Sequencing 16S Sequencing Whole Genome Sequencing Others Application Insights (Revenue, USD Bn, 2020 - 2032) Drug Discovery Clinical Diagnostics Others End User Insights (Revenue, USD Bn, 2020 - 2032) Pharmaceutical Companies Research Laboratories Others Regional Insights (Revenue, USD Bn, 2020 - 2032) North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa Central Africa About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
National Post
an hour ago
- National Post
Loomis Sayles Celebrates 15 Years of Growth Equity Strategies Team Under Leadership of Aziz V. Hamzaogullari
Article content Article content Loomis, Sayles & Company proudly celebrates the 15-year anniversary of a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm's Board of Directors. Article content GES is a cohesive team with nearly 19 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari's leadership since 2010, assets under management for GES have grown from $1.9 billion to nearly $91 billion as of 31 May 2025. Article content Aziz brought a differentiated approach to equity investing when he joined Loomis Sayles in 2010. A proprietary seven-step research framework supports the GES Team's long-term, private equity approach to investing. The Team seeks to invest in those few high-quality businesses with sustainable competitive advantages and profitable growth only when they trade at a discount to the GES estimate of intrinsic value. Article content Underpinned by this singular investment philosophy, the GES Team expanded its platform from US-focused Large Cap Growth and All Cap Growth strategies to also include Global Growth, International Growth long-only strategies as well as the Long/Short Growth Equity hedge fund strategy. These strategies also are available in vehicles available to US investors. Article content The GES Team believes a focus on the quality of a manager's investment philosophy, process and decision-making is essential for assessing the probability of future success. The GES alpha thesis encapsulates a deeply held system of persistent beliefs, a rigorous, repeatable investment process and substantive proof points. Article content 'Since joining Loomis Sayles in 2010, Aziz and the GES Team have consistently distinguished themselves through a relentless focus on striving to achieve superior risk-adjusted returns for investors. Backed by their differentiated approach, they have demonstrated skilled and disciplined decision-making as well as a strong performance track record of which we are very proud,' said Kevin Charleston, chief executive officer of Loomis Sayles. 'I would like to thank our investors for their trust. We will continue to be committed to our guiding principles of long-term investing based on our key differentiated insights,' said Aziz V. Hamzaogullari, CFA, founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies Team. Article content The cohesive GES Team has nearly 19 years of strong alpha generation in its domestic, global, international and long/short growth equity strategies as shown below. Article content LONG-SHORT GROWTH EQUITY COMPOSITE As of 3/31/2025 INCEPTION DATE ALPHA* (gross) ALPHA* (net) Long/Short Growth Equity 2/1/2012^ 5.61 4.23 *Alpha calculated against S&P 500 (Large Cap Growth), S&P 500 (All Cap Growth), MSCI ACWI (Global Growth), MSCI ACWI ex-US (International Growth), S&P 500 (Long/Short Growth Equity). The benchmark for the Large Cap Growth Managed Account Composite is the Russell 1000 Growth Index. The benchmark for the All Cap Growth Managed Account Composite is the Russell 3000 Growth Index. The Long/Short Growth Equity Managed Account is benchmark agnostic. Performance for the S&P 500 Index is shown as supplemental information as it's widely used as the barometers of the US stock market. **Rankings out of 159 observations. (eVestment Alliance's Large Cap Growth Universe.) Ranking out of 37 observations. (eVestment Alliance's All Cap Growth Universe.) Ranking out of 776 observations. (eVestment Alliance's Global Large Cap and Global All Cap Equity Universes). Ranking out of 241 observations (eVestment Alliance's ACWI ex-US Large Cap and ACWI ex-US All Cap Equity.) Rankings are since inception, based on gross returns, and subject to change. ^Calculated since initiation of short exposures on 5/23/2012, although no investor was offered the opportunity to invest as of such date. Additional short positions were initiated 4/4/2014 – 4/7/2014. Source: Loomis Sayles, eASE Analytics System; eVestment Alliance is the ranking agency, as of 3/31/2025 Article content Article content Inception 7/1/2006 Article content Article content $84.1 BILLION AUM Article content Since inception in 2006, the Large Cap Growth composite has generated an annualized return of 14.19% (gross), 13.68% (net), outperforming the Russell 1000 Growth Index by 1.63% (gross), 1.12% (net), a gross return that ranks ahead of 98% of large cap growth peers. † The Large Cap Growth composite seeks to produce long-term, excess returns vs. the Russell 1000® Growth Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection. Article content Past performance is no guarantee of future results. Article content Gross returns are net of trading costs. Net returns are gross returns less effective management fees. Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index Please see trailing returns and other statistics as of the most recent quarter-end at the end of the document. Article content † Article content Ranking out of 159 observations (eVestment Alliance's Large Cap Growth Universe.) Article content Article content Inception 7/1/2006 Article content Article content $3.3 BILLION AUM Article content Since inception in 2006, the All Cap Growth composite has generated an annualized return of 14.14% (gross), 13.55% (net), outperforming the Russell 3000 Growth Index by 1.89% (gross), 1.30% (net), a gross return that ranks ahead of 95% of category peers**. Article content The All Cap Growth composite seeks to produce long-term, excess returns vs. the Russell 3000 ® Growth Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection. Article content GLOBAL GROWTH Article content Article content Inception 1/1/2016 Article content Article content $2.6 BILLION AUM Article content Since inception in 2016, the Global Growth composite has generated an annualized return of 13.55% (gross), 12.79% (net), outperforming the MSCI ACWI Gross Index by 2.85% (gross), 2.10% (net), a gross return that ranks ahead of 94% of global growth peers**. Article content The Global Growth composite seeks to produce long-term, excess returns vs. MSCI ACWI Gross Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection. Article content Article content Inception 1/1/2020 Article content Article content $45.8 MILLION AUM Article content Since inception in 2020, the International Growth composite has generated an annualized return of 7.03% (gross), 6.18% (net), outperforming the MSCI ACWI ex-US Gross Index by 1.60% (gross), 0.75% (net), a gross return that ranks ahead of 62% of international growth peers**. Article content The International Growth composite seeks to produce long-term, excess returns vs. MSCI ACWI ex-US Gross Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection. Article content LONG/SHORT GROWTH EQUITY Article content Article content Inception 2/1/2012 Article content Article content $655.9 MILLION AUM Article content Since 2012, the Long/Short Growth Equity composite has generated an annualized return of 10.97% (gross), 9.33% (net), outperforming the S&P 500 50% Hedged Index by 3.89% (gross), 2.25% (net), the HFRI Equity Hedge (Total) Index * by 4.47% (gross), 2.83% (net) and the HFRI EH: Fundamental Growth Index by 5.61% (gross), 3.97 (net). Article content The Long/Short Growth Equity composite seeks to generate attractive long-term absolute positive returns regardless of market direction. Article content * The HFRI Equity Hedge (Total) Asset Weighted Composite Index is a global, asset-weighted index comprised of a single-manager funds that report to HFR Database. It is comprised of Equity Hedge fund peers that are not considered Equity Market Neutral. This index is being shown for informational and reference purposes only. Source: Loomis Sayles, FTSE Russell, MSCI & HFR, as of 31 March 2025 The Portfolio Manager for the Growth Equity Strategies joined Loomis Sayles May 19, 2010, and his performance prior to that date was achieved at his prior firm. Gross returns are net of trading costs. Net returns are gross returns less effective management fees. Returns may increase or decrease as a result of currency fluctuations. Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index. Any investment that has the possibility for profits also has the possibility of losses, including the loss of principal. Please request a current presentation book for each strategy for more information regarding risks and GIPS reports. Please see trailing returns and other statistics as of the most recent quarter-end at the end of the document. **Rankings out of 37 observations (eVestment Alliance's All Cap Growth Universe.) Ranking out of 821 observations. (eVestment Alliance's Global Large Cap and Global All Cap Equity Universes). Ranking out of 248 observations (eVestment Alliance's ACWI ex-US Large Cap and ACWI ex-US All Cap Equity.) Past performance is no guarantee of future results. Article content Market Risk Article content Non-US Securities Risk Article content Article content The risk that the value of non-US investments will fall as a result of political, social, economic or currency factors or other issues relating to non-US investing generally. Among other things, nationalization, expropriation or confiscatory taxation, currency blockage, political changes or diplomatic developments can negatively impact the value of investments. Non-US securities markets may be relatively small or underdeveloped, and non-US companies may not be subject to the same degree of regulation or reporting requirements as comparable US companies. This risk is heightened for underdeveloped or emerging markets, which may be more likely to experience political or economic stability than larger, more established countries. Settlement issues may occur. Article content The risk that the equity securities of these companies may be subject to more abrupt price movements, limited markets and less liquidity than investments in larger, more established companies. Article content Article content The risk that the strategy may be unable to find a buyer for its investments when it seeks to sell them. Article content Article content Non-Diversified Strategies Article content Article content Non-diversified strategies tend to be more volatile than diversified strategies and the market as a whole. Article content Article content Currency Risk Article content The risk that the value of investments will fall as a result of changes in exchange rates, particularly for global portfolios. Article content Article content Derivatives Risk (for portfolios that utilize derivatives) Article content Article content The risk that the value of the Strategy's derivatives instruments will fall because of changes in the value of the underlying reference instrument, pricing difficulties or lack of correlation with the underlying investment. Article content Article content Article content The risk of increased loss in value or volatility due to the use of leverage or obtaining investment exposure greater than the value of an account. Article content Article content Counterparty Risk Article content Article content The risk that the counterparty to a swap or other derivatives contract will default on its obligations. Article content Article content Models and Data Risk Article content Article content The strategy may utilize quantitative model-based strategies. This is the risk that one or all of the quantitative or systematic models used may fail to identify profitable opportunities at any time. These models may incorrectly identify opportunities and these misidentified opportunities may lead to substantial losses. Models may be predictive in nature and may result in an incorrect assessment of future events. Data used in the construction of models may prove to be inaccurate or stale, which may result in investment losses. Article content General Risk Article content Article content Equity Risk Article content Article content The risk that the value of the Strategy's investments in equity securities is subject to the risks of unpredictable declines in the value of individual securities and periods of below-average performance in individual securities or in the equity market as a whole. Article content Short Sale Risk Article content The risk of losing an amount greater than the amount initially invested. Short selling is limited only by the maximum attainable price of the security less the price at which it was sold and is considered a form of leverage. Article content Article content The risk that the value of non-US investments will fall as a result of political, social, economic or currency factors or other issues relating to non-US investing generally. Among other things, nationalization, expropriation or confiscatory taxation, currency blockage, political changes or diplomatic developments can negatively impact the value of investments. This risk is heightened for underdeveloped or emerging markets, which may be more likely to experience political or economic stability than larger, more established countries. Settlement issues may occur. Article content Article content Currency Risk Article content Article content Derivatives Risk Article content Article content The risk that the value of the Strategy's derivatives instruments will fall because of changes in the value of the underlying reference instrument, pricing difficulties or lack of correlation with the underlying investment. Article content Article content Leverage Risk Article content The risk of increased loss in value or volatility due to the use of leverage or obtaining investment exposure greater than the value of an account. Article content Article content Counterparty Risk Article content Article content The risk that the counterparty to a derivatives contract will default on its obligations. Article content Strategies referenced herein are managed by Loomis, Sayles & Company, L.P. Article content CFA® and Chartered Financial Analyst® are registered trademarks owned by the CFA Institute. Article content Diversification does not ensure a profit or guarantee against a loss. Article content Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index. Article content This material is not intended to provide tax, legal, insurance, or investment advice. Please seek appropriate professional expertise for your needs. Article content Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent. Article content ALL CAP GROWTH COMPOSITE TRAILING RETURNS AND RANKS AS OF 3/31/2025 (%) 1 Year Rank 5 Years Rank 10 Years Rank All Cap Growth (gross) 9.23 12 18.02 31 15.23 8 All Cap Growth (net) 8.50 14 17.34 31 14.61 12 Russell 3000 Growth Index 7.18 24 19.57 16 14.55 14 Ranking out of 68 observations (1-Year), 62 observations (5-Year) and 55 observations (10-Year) and 37 observations (Since Inception). (eVestment Alliance's All Cap Growth Universe.) Article content GLOBAL GROWTH COMPOSITE TRAILING RETURNS AND RANKS AS OF 3/31/2025 (%) 1 Year Rank 5 Years Rank Since Inception 1/1/2016 Rank Global Growth (gross) 11.99 9 15.97 37 13.54 6 Global Growth (net) 11.17 11 15.23 36 12.79 6 MSCI ACWI Index Gross 7.63 31 15.71 40 10.70 40 Ranking out of 1,338 observations (1-Year), 1,132 observations (5-Year) and 821 observations (Since Inception). (eVestment Alliance's Global Large Cap and Global All Cap Equity Blended Universes.) Performance data shown represents past performance and is no guarantee of future results. Current performance may be lower or higher than quoted. Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index. Gross returns are net of trading costs. Net returns are gross returns less effective management fees. Returns may increase or decrease as a result of currency fluctuations. Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index. Annualized performance is calculated as the geometric mean of the product's returns with respect to one year. The highest (or most favorable) percentile rank is 1, and the lowest (or least favorable) percentile rank is 100. Rankings are subject to change. Although we believe it is reliable, we cannot guarantee the accuracy of data from a third party source Article content INTERNATIONAL GROWTH TRAILING RETURNS AND RANKS AS OF 3/31/2025 (%) 1 Year Rank 5 Years Rank Since Inception 1/1/2020 Rank International Growth (gross) 7.39 43 11.16 65 7.03 38 International Growth (net) 6.54 44 10.29 68 6.18 40 MSCI ACWI ex-US Index Gross 6.65 49 11.46 63 5.43 68 Ranking out of 278 observations (1-Year), 251 observations (5-Year) and 248 observations (Since Inception). (eVestment Alliance's ACWI ex-US Large Cap and ACWI ex-US All Cap Equity Blended Universes.) Article content LONG/SHORT GROWTH EQUITY TRAILING RETURNS AS OF 3/31/2025 (%) 1 Year 5 Years 10 Years Long/Short Growth Equity (gross) 21.51 10.24 9.47 Long/Short Growth Equity (net) 16.94 7.43 6.64 Source: Loomis Sayles. As of 31 March 2025; Performance for multi-year periods is annualized. The portfolio manager for the Growth Equity Strategies joined Loomis Sayles on May 19, 2010, and performance prior to that date was achieved at his prior firm. The prior performance information is being included as part of the Loomis Sayles Large Cap Growth Composite. Gross returns are net of trading costs. Net returns are gross returns less effective management fees. Annualized performance is calculated as the geometric mean of the product's returns with respect to one year. The highest (or most favorable) percentile rank is 1, and the lowest (or least favorable) percentile rank is 100. Rankings are subject to change. Although we believe it is reliable, we cannot guarantee the accuracy of data from a third party source. This information cannot be copied, reproduced or redistributed without authorization in any form. Performance data shown represents past performance and is no guarantee of future results. Current performance may be lower or higher than quoted. Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index. Article content ABOUT LOOMIS SAYLES Article content Since 1926, Loomis, Sayles & Company has helped fulfill the investment needs of institutional and mutual fund clients worldwide. The firm's performance-driven investors integrate deep proprietary research and risk analysis to make informed, judicious decisions. Teams of portfolio managers, strategists, research analysts and traders collaborate to assess market sectors and identify investment opportunities wherever they may lie, within traditional asset classes or among a range of alternative investments. Loomis Sayles has the resources, foresight and the flexibility to look far and wide for value in broad and narrow markets in its commitment to deliver attractive, risk-adjusted returns for clients. This rich tradition has earned Loomis Sayles the trust and respect of clients worldwide, for whom it manages $390.1 billion* in assets (as of 31 March 2025). Article content *Includes the assets of both Loomis, Sayles & Co., LP, and Loomis Sayles Trust Company, LLC. ($33.9 billion for the Loomis Sayles Trust Company). Loomis Sayles Trust Company is a wholly owned subsidiary of Loomis, Sayles & Company, L.P. Article content Article content Article content Article content Article content
